Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Metrics to compare | 4598 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4598PeersSector | |
---|---|---|---|---|
P/E Ratio | −3.8x | −9.5x | −0.5x | |
PEG Ratio | −2.41 | 0.00 | 0.00 | |
Price/Book | 23.8x | 4.8x | 2.6x | |
Price / LTM Sales | - | 24.5x | 3.3x | |
Upside (Analyst Target) | - | 58.3% | 43.5% | |
Fair Value Upside | Unlock | 11.3% | 6.8% | Unlock |